A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

INTRODUCTION: Since sipuleucel-T approval in 2010, the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) now includes the androgen-receptor signaling pathway inhibitors (ASPIs) abiraterone acetate or enzalutamide. In 2013 and 2014, these oral agents were approved for us...

Descripción completa

Detalles Bibliográficos
Autores principales: McKay, Rana R., Hafron, Jason M., Ferro, Christine, Wilfehrt, Helen M., Fitch, Kate, Flanders, Scott C., Fabrizio, Michael D., Schweizer, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596004/
https://www.ncbi.nlm.nih.gov/pubmed/33029725
http://dx.doi.org/10.1007/s12325-020-01509-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596004/
https://www.ncbi.nlm.nih.gov/pubmed/33029725
http://dx.doi.org/10.1007/s12325-020-01509-5

Ejemplares similares